Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
Purpose
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy.
Conditions
- Advanced Melanoma
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Melanoma of Unknown Primary
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Unresectable Acral Lentiginous Melanoma
- Unresectable Melanoma
- Unresectable Mucosal Melanoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- STEP 0 PRE-REGISTRATION INCLUSION CRITERIA - Patient must have active advanced melanoma, defined as unresectable stage IIIB-IV by American Joint Committee on Cancer (AJCC) 8th edition - Patient must have melanoma originating from cutaneous, acral-lentiginous, or mucosal primary sites. Patients with melanoma of unknown primary site are eligible. Patients must not have melanoma from an ocular primary site - Patient must have had measurable disease by immune related Response Evaluation Criteria in Solid Tumors (imRECIST) prior to start of initial anti-PD-1 therapy - Patient must be actively receiving standard of care anti-PD-1 therapy, currently be 52 weeks (+/- 2 weeks) from start of anti-PD-1 therapy, and have not experienced a toxicity that prevents them from continuing on therapy. Permitted systemic anti-PD-1 therapy regimens include: - Nivolumab 240 mg IV every (Q)2weeks or 480 mg IV Q4weeks - Pembrolizumab 200 mg IV Q3weeks or 400 mg IV Q6weeks - Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg IV Q3weeks induction x 4 doses, followed by nivolumab 240 mg IV Q2weeks or 480 mg IV Q4weeks maintenance - Nivolumab 3 mg/kg plus Ipilimumab 1 mg/kg IV Q3weeks induction x 4 doses, followed by nivolumab 240 mg IV Q2weeks or 480 mg IV Q4weeks maintenance - Pembrolizumab 2 mg/kg (or 200 mg flat dose) plus Ipilimumab 1 mg/kg IV Q3weeks induction x 4 doses, followed by pembrolizumab 200 mg IV Q3weeks or 400 mg IV Q6weeks maintenance - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Patients with detectable viral loads are excluded as it is unclear if these patients have a low risk of melanoma progression off anti-PD-1 treatment - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial - Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better - Patient must have experienced complete response, partial response, or stable disease on restaging CT scans by imRECIST that is maintained on restaging scans obtained at week 52 (+/- 2 weeks) from start of initial anti-PD-1 therapy - Patient must have completed an FDG-PET/CT scan at week 52 (+/- 2 weeks) from start of initial anti-PD-1 therapy - Patients with PET/CT positive for hypermetabolic lesions: If a core needle, punch or excisional biopsy and pathological review of a representative lesion was not performed prior to pre-registration (Step 0) must either: - Be amenable to undergo a biopsy. Patient must not be on anticoagulation therapy or, if on anti-coagulation therapy, patient must be able to hold treatment for a biopsy procedure (core needle, punch or excisional biopsy). Anti-coagulation therapy is defined as low molecular weight heparin, warfarin, factor Xa inhibitor, or direct thrombin inhibitor - Have documentation of inability to perform the biopsy due to feasibility or safety concerns - Leukocytes >= 3,000/mcL (obtained =< 4 weeks prior to protocol registration) - Absolute neutrophil count >= 1,500/mcL (obtained =< 4 weeks prior to protocol registration) - Platelets >= 100,000/mcL (obtained =< 4 weeks prior to protocol registration) - Total bilirubin =< institutional upper limit of normal (ULN) (patients with history of Gilbert's syndrome are permitted to have a total bilirubin > 1.5 x institutional ULN) (obtained =< 4 weeks prior to protocol registration) - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (obtained =< 4 weeks prior to protocol registration) - Creatinine =< 1.5 x institutional ULN (obtained =< 4 weeks prior to protocol registration) - STEP 1 REGISTRATION INCLUSION CRITERIA - Patient met all eligibility criteria outlined above - Patient must register to Step 1 within 4 weeks of registration to Step 0 - Patients must meet one of the following criteria: - Patient had no positive hypermetabolic lesions on the week 52 FDG-PET/CT. - Patients with positive hypermetabolic lesion(s) on the week 52 FDG-PET/CT (positive hypermetabolic = standard uptake volume [SUV] > pooled mediastinal blood), one of the following must have occurred: - A representative lesion was biopsied (core needle, punch or excisional biopsy) within 14 days of registration to Step 0 and subsequent pathology review performed to determine the presence or absence of viable tumor - Documentation is present that the patient is not able to undergo biopsy of a hypermetabolic lesion due to feasibility or safety concerns, i.e., the lesion location that is not amenable to biopsy
Exclusion Criteria
- STEP 0 PRE-REGISTRATION EXCLUSION CRITERIA - Patient must not be receiving concurrent anti-tumor therapies in addition to the standard of care anti-PD-1 regimens. Patients who are receiving bisphosphonates and RANKL inhibitors for management of bone metastases are eligible - Patient must not have brain metastases - Women must not be pregnant or breast-feeding due to potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the anti-PD-1 regimens being used. All females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) - Women of childbearing potential and sexually active males must not conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of study registration and continuing until at least 5 months after the last dose of anti-PD-1 treatment for female patients and for at least 7 months after the last dose of anti-PD-1 treatment for male patients who are sexually active with a women of childbearing potential (WOCBP)
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Non-Randomized
- Intervention Model
- Sequential Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Arm A (active surveillance) |
Patients with a negative FDG-PET/CT scan or a positive FDG-PET/CT scan but with a negative biopsy for viable tumor discontinue the anti-PD-1 therapy and undergo active surveillance. |
|
Active Comparator Arm B (nivolumab, pembrolizumab, ipilimumab) |
Patients with a positive FDG-PET/CT scan and positive biopsy for viable tumor or a positive FDG-PET/CT scan and biopsy not performed continue their standard of care anti-PD-1 therapy for 12 months in the absence of disease progression or unacceptable toxicity. |
|
Other Standard of Care (nivolumab, pembrolizumab, ipilimumab) |
Patients continue their standard of care anti-PD-1 therapy. Treatment may consist of the following regimens: 1) nivolumab IV over 30 minutes Q2W or Q4W; 2) pembrolizumab IV over 30 minutes Q3W or Q6W; 3) nivolumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by nivolumab IV over 30 minutes Q2W or Q4W; or 4) pembrolizumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by pembrolizumab IV over 30 minutes Q3W or Q6W. Treatment continues until 52 weeks from start of standard of care anti-PD-1 therapy in the absence of disease progression or unacceptable toxicity. |
|
Recruiting Locations
Fairhope 4061234, Alabama 4829764 36532
Site Public Contact
251-435-4584
Mobile 4076598, Alabama 4829764 36607
Site Public Contact
251-435-3942
Fairbanks 5861897, Alaska 5879092 99701
Phoenix 5308655, Arizona 5551752 85004
Tucson 5318313, Arizona 5551752 85719
Tucson 5318313, Arizona 5551752 85719
Fort Smith 4111410, Arkansas 4099753 72903
Site Public Contact
800-378-9373
Little Rock 4119403, Arkansas 4099753 72205
Little Rock 4119403, Arkansas 4099753 72205
Site Public Contact
501-686-8274
Antioch 5324200, California 5332921 94531
Arroyo Grande 5324802, California 5332921 93420
Carmichael 5334336, California 5332921 95608
Carmichael 5334336, California 5332921 95608
Dublin 5344157, California 5332921 94568
Site Public Contact
877-642-4691
Elk Grove 5346111, California 5332921 95758
Fremont 5350734, California 5332921 94538
Fresno 5350937, California 5332921 93720
Fresno 5350937, California 5332921 93720
Los Angeles 5368361, California 5332921 90025
Los Angeles 5368361, California 5332921 90048
Site Public Contact
310-423-8965
Merced 5372253, California 5332921 95340
Modesto 5373900, California 5332921 95356
Oakland 5378538, California 5332921 94611
Oakland 5378538, California 5332921 94611
Rancho Cordova 5385941, California 5332921 95670
Redwood City 5386834, California 5332921 94063
Site Public Contact
877-642-4691
Richmond 5387428, California 5332921 94801
Rocklin 5388319, California 5332921 95765
Rohnert Park 5388564, California 5332921 94928
Roseville 5388881, California 5332921 95661
Roseville 5388881, California 5332921 95678
Sacramento 5389489, California 5332921 95814
Sacramento 5389489, California 5332921 95816
Sacramento 5389489, California 5332921 95823
Sacramento 5389489, California 5332921 95823
San Francisco 5391959, California 5332921 94115
San Jose 5392171, California 5332921 95119
San Leandro 5392263, California 5332921 94577
San Luis Obispo 5392323, California 5332921 93401
San Rafael 5392567, California 5332921 94903
Santa Clara 5393015, California 5332921 95051
Santa Maria 5393180, California 5332921 93444
Santa Rosa 5393287, California 5332921 95403
South San Francisco 5397765, California 5332921 94080
South San Francisco 5397765, California 5332921 94080
Stockton 5399020, California 5332921 95210
Vacaville 5405228, California 5332921 95688
Vallejo 5405380, California 5332921 94589
Walnut Creek 5406990, California 5332921 94596
Walnut Creek 5406990, California 5332921 94598
Woodland 5410430, California 5332921 95695
Aurora 5412347, Colorado 5417618 80012
Boulder 5574991, Colorado 5417618 80303
Boulder 5574991, Colorado 5417618 80304
Centennial 5416541, Colorado 5417618 80112
Colorado Springs 5417598, Colorado 5417618 80907
Colorado Springs 5417598, Colorado 5417618 80907
Colorado Springs 5417598, Colorado 5417618 80923
Denver 5419384, Colorado 5417618 80205
Denver 5419384, Colorado 5417618 80209
Denver 5419384, Colorado 5417618 80218
Denver 5419384, Colorado 5417618 80218
Denver 5419384, Colorado 5417618 80220
Durango 5420241, Colorado 5417618 81301
Durango 5420241, Colorado 5417618 81301
Englewood 5421250, Colorado 5417618 80113
Englewood 5421250, Colorado 5417618 80113
Lafayette 5427771, Colorado 5417618 80026
Lakewood 5427946, Colorado 5417618 80228
Lakewood 5427946, Colorado 5417618 80228
Littleton 5429032, Colorado 5417618 80120
Lone Tree 5429208, Colorado 5417618 80124
Lone Tree 5429208, Colorado 5417618 80124
Longmont 5579276, Colorado 5417618 80501
Longmont 5579276, Colorado 5417618 80501
Pueblo 5435464, Colorado 5417618 81004
Thornton 5441492, Colorado 5417618 80260
Washington D.C. 4140963, District of Columbia 4138106 20007
Site Public Contact
202-444-2223
Washington D.C. 4140963, District of Columbia 4138106 20010
Site Public Contact
202-877-8839
Aventura 4146429, Florida 4155751 33180
Site Public Contact
954-461-2180
Coral Gables 4151871, Florida 4155751 33146
Site Public Contact
305-243-2647
Deerfield Beach 4153071, Florida 4155751 33442
Site Public Contact
305-243-2647
Fort Lauderdale 4155966, Florida 4155751 33308
Miami 4164138, Florida 4155751 33136
Site Public Contact
305-243-2647
Miami 4164138, Florida 4155751 33176
Site Public Contact
305-243-2647
Plantation 4168782, Florida 4155751 33324
Site Public Contact
305-243-2647
Atlanta 4180439, Georgia 4197000 30322
Site Public Contact
404-778-1868
Atlanta 4180439, Georgia 4197000 30342
Duluth 4192289, Georgia 4197000 30096
Lawrenceville 4205196, Georgia 4197000 30046
Honolulu 5856195, Hawaii 5855797 96819
Boise 5586437, Idaho 5596512 83706
Caldwell 5587698, Idaho 5596512 83605
Coeur d'Alene 5589173, Idaho 5596512 83814
Emmett 5592562, Idaho 5596512 83617
Meridian 5600685, Idaho 5596512 83642
Nampa 5601933, Idaho 5596512 83687
Post Falls 5604353, Idaho 5596512 83854
Sandpoint 5606401, Idaho 5596512 83864
Alton 4232679, Illinois 4896861 62002
Site Public Contact
618-463-5623
Bloomington 4885164, Illinois 4896861 61704
Canton 4831990, Illinois 4896861 61520
Carbondale 4235193, Illinois 4896861 62902
Carterville 4235311, Illinois 4896861 62918
Carthage 4886716, Illinois 4896861 62321
Centralia 4235587, Illinois 4896861 62801
Centralia 4235587, Illinois 4896861 62801
Chicago 4887398, Illinois 4896861 60611
Chicago 4887398, Illinois 4896861 60612
Site Public Contact
312-355-3046
Decatur 4236895, Illinois 4896861 62526
Decatur 4236895, Illinois 4896861 62526
Dixon 4889959, Illinois 4896861 61021
Site Public Contact
815-285-7800
Effingham 4237727, Illinois 4896861 62401
Elmhurst 4891010, Illinois 4896861 60126
Eureka 4891310, Illinois 4896861 61530
Galesburg 4893392, Illinois 4896861 61401
Galesburg 4893392, Illinois 4896861 61401
Site Public Contact
309-344-2831
Kewanee 4898433, Illinois 4896861 61443
Macomb 4900817, Illinois 4896861 61455
Mount Vernon 4245152, Illinois 4896861 62864
Site Public Contact
618-242-4600
Naperville 4903279, Illinois 4896861 60540
Site Public Contact
630-646-6075
O'Fallon 4245926, Illinois 4896861 62269
O'Fallon 4245926, Illinois 4896861 62269
Ottawa 4905006, Illinois 4896861 61350
Pekin 4905599, Illinois 4896861 61554
Peoria 4905687, Illinois 4896861 61615
Peoria 4905687, Illinois 4896861 61636
Peru 4905770, Illinois 4896861 61354
Peru 4905770, Illinois 4896861 61354
Site Public Contact
815-664-4141
Plainfield 4906125, Illinois 4896861 60585
Princeton 4906818, Illinois 4896861 61356
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
217-545-7929
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
800-444-7541
Springfield 4250542, Illinois 4896861 62781
Washington 4915545, Illinois 4896861 61571
Ankeny 4846960, Iowa 4862182 50023
Site Public Contact
515-282-2921
Carroll 4850478, Iowa 4862182 51401
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-6727
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-3305
Des Moines 4853828, Iowa 4862182 50314
Site Public Contact
515-282-2200
Des Moines 4853828, Iowa 4862182 50316
Site Public Contact
515-241-8704
Fort Dodge 4857486, Iowa 4862182 50501
Site Public Contact
515-574-8302
West Des Moines 4881346, Iowa 4862182 50266-7700
Site Public Contact
515-343-1000
Garden City 5445439, Kansas 4273857 67846
Great Bend 4272340, Kansas 4273857 67530
Bardstown 4283133, Kentucky 6254925 40004
Corbin 4288656, Kentucky 6254925 40701
Lexington 4297983, Kentucky 6254925 40504
Lexington 4297983, Kentucky 6254925 40504
Lexington 4297983, Kentucky 6254925 40509
London 4298960, Kentucky 6254925 40741
Mount Sterling 4301683, Kentucky 6254925 40353
Paducah 4048662, Kentucky 6254925 42003
Baltimore 4347778, Maryland 4361885 21237
Site Public Contact
443-777-7364
Boston 4930956, Massachusetts 6254926 02118
Site Public Contact
617-638-8265
Adrian 4983811, Michigan 5001836 49221
Site Public Contact
517-265-0116
Ann Arbor 4984247, Michigan 5001836 48106
Battle Creek 4985153, Michigan 5001836 49017
Brighton 4986994, Michigan 5001836 48114
Brighton 4986994, Michigan 5001836 48114
Canton 4987990, Michigan 5001836 48188
Canton 4987990, Michigan 5001836 48188
Caro 4988059, Michigan 5001836 48723
Chelsea 4988628, Michigan 5001836 48118
Chelsea 4988628, Michigan 5001836 48118
Clarkston 4988997, Michigan 5001836 48346
Clarkston 4988997, Michigan 5001836 48346
Detroit 4990729, Michigan 5001836 48236
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48503
Grand Rapids 4994358, Michigan 5001836 49503
Grand Rapids 4994358, Michigan 5001836 49503
Grand Rapids 4994358, Michigan 5001836 49503
Kalamazoo 4997787, Michigan 5001836 49007
Kalamazoo 4997787, Michigan 5001836 49007
Kalamazoo 4997787, Michigan 5001836 49009
Kalamazoo 4997787, Michigan 5001836 49048
Lansing 4998830, Michigan 5001836 48912
Livonia 4999837, Michigan 5001836 48154
Marlette 5000938, Michigan 5001836 48453
Monroe 5002344, Michigan 5001836 48162
Site Public Contact
800-444-3561
Muskegon 5003132, Michigan 5001836 49444
Niles 5003514, Michigan 5001836 49120
Site Public Contact
616-391-1230
Norton Shores 5004005, Michigan 5001836 49444
Pontiac 5006166, Michigan 5001836 48341
Pontiac 5006166, Michigan 5001836 48341
Pontiac 5006166, Michigan 5001836 48341
Pontiac 5006166, Michigan 5001836 48341
Reed City 5006946, Michigan 5001836 49677
Saginaw 5007989, Michigan 5001836 48601
Saginaw 5007989, Michigan 5001836 48604
Saint Joseph 5008327, Michigan 5001836 49085
Saint Joseph 5008327, Michigan 5001836 49085
Tawas City 5011900, Michigan 5001836 48764
Traverse City 5012495, Michigan 5001836 49684
Warren 5014051, Michigan 5001836 48093
West Branch 5014413, Michigan 5001836 48661
Wyoming 5015618, Michigan 5001836 49519
Ypsilanti 5015688, Michigan 5001836 48106
Ypsilanti 5015688, Michigan 5001836 48197
Aitkin 5015978, Minnesota 5037779 56431
Baxter 5017396, Minnesota 5037779 56425
Site Public Contact
218-828-2880
Bemidji 5017822, Minnesota 5037779 56601
Brainerd 5019116, Minnesota 5037779 56401
Deer River 5024099, Minnesota 5037779 56636
Detroit Lakes 5024237, Minnesota 5037779 56501
Duluth 5024719, Minnesota 5037779 55805
Duluth 5024719, Minnesota 5037779 55805
Duluth 5024719, Minnesota 5037779 55805
Ely 5025627, Minnesota 5037779 55731
Site Public Contact
218-365-7900
Fosston 5027191, Minnesota 5037779 56542
Hibbing 5030005, Minnesota 5037779 55746
Site Public Contact
218-786-3308
International Falls 5031404, Minnesota 5037779 56649
Site Public Contact
218-283-9431
Moose Lake 5038132, Minnesota 5037779 55767
Site Public Contact
218-485-4481
Park Rapids 5040822, Minnesota 5037779 56470
Saint Cloud 5044407, Minnesota 5037779 56303
Sandstone 5045908, Minnesota 5037779 55072
Thief River Falls 5049970, Minnesota 5037779 56701
Site Public Contact
605-312-3320
Virginia 5051468, Minnesota 5037779 55792
Worthington 5053460, Minnesota 5037779 56187
Site Public Contact
605-312-3320
Ballwin 4375663, Missouri 4398678 63011
Site Public Contact
314-251-7058
Bolivar 4377835, Missouri 4398678 65613
Branson 4378219, Missouri 4398678 65616
Site Public Contact
417-269-4520
Cape Girardeau 4379966, Missouri 4398678 63703
Cape Girardeau 4379966, Missouri 4398678 63703
Site Public Contact
573-651-5550
Farmington 4386289, Missouri 4398678 63640
Site Public Contact
314-996-5569
Joplin 4392768, Missouri 4398678 64804
Joplin 4392768, Missouri 4398678 64804
Osage Beach 4402040, Missouri 4398678 65065
Rolla 4406282, Missouri 4398678 65401
Rolla 4406282, Missouri 4398678 65401
Site Public Contact
573-458-6379
Saint Joseph 4407010, Missouri 4398678 64506
Sainte Genevieve 4407294, Missouri 4398678 63670
Site Public Contact
314-996-5569
Springfield 4409896, Missouri 4398678 65804
Site Public Contact
417-269-4520
Springfield 4409896, Missouri 4398678 65807
Site Public Contact
417-269-4520
St Louis 4407066, Missouri 4398678 63109
Site Public Contact
314-353-1870
St Louis 4407066, Missouri 4398678 63128
St Louis 4407066, Missouri 4398678 63131
Site Public Contact
314-996-5569
St Louis 4407066, Missouri 4398678 63141
Site Public Contact
314-251-7066
Sullivan 4410669, Missouri 4398678 63080
Site Public Contact
314-996-5569
Sunset Hills 4410836, Missouri 4398678 63127
Site Public Contact
314-996-5569
Washington 4413621, Missouri 4398678 63090
Site Public Contact
636-390-1600
Anaconda 5637146, Montana 5667009 59711
Billings 5640350, Montana 5667009 59101
Bozeman 5641727, Montana 5667009 59715
Great Falls 5655240, Montana 5667009 59405
Great Falls 5655240, Montana 5667009 59405
Kalispell 5660340, Montana 5667009 59901
Missoula 5666639, Montana 5667009 59804
Kearney 5071348, Nebraska 5073708 68847
Omaha 5074472, Nebraska 5073708 68122
Omaha 5074472, Nebraska 5073708 68124
Omaha 5074472, Nebraska 5073708 68130
Omaha 5074472, Nebraska 5073708 68131
Hackensack 5098706, New Jersey 5101760 07601
Site Public Contact
551-996-2897
Middletown 5101170, New Jersey 5101760 07748
Site Public Contact
212-639-7592
Montvale 5101361, New Jersey 5101760 07645
Site Public Contact
212-639-7592
Neptune City 5101687, New Jersey 5101760 07753
Site Public Contact
732-776-4240
Red Bank 5103159, New Jersey 5101760 07701
Site Public Contact
732-530-2382
Albuquerque 5454711, New Mexico 5481136 87106
East White Plains 5116104, New York 5128638 10604
Site Public Contact
212-639-7592
Glens Falls 5118693, New York 5128638 12801
Site Public Contact
518-926-6700
New York 5128581, New York 5128638 10016
Cary 4459467, North Carolina 4482348 27518
Site Public Contact
919-781-7070
Chapel Hill 4460162, North Carolina 4482348 27599
Durham 4464368, North Carolina 4482348 27710
Site Public Contact
888-275-3853
Greenville 4469160, North Carolina 4482348 27834
Raleigh 4487042, North Carolina 4482348 27607
Site Public Contact
919-785-4878
Raleigh 4487042, North Carolina 4482348 27609
Site Public Contact
919-862-5400
Bismarck 5688025, North Dakota 5690763 58501
Fargo 5059163, North Dakota 5690763 58103
Fargo 5059163, North Dakota 5690763 58103
Site Public Contact
701-234-6161
Fargo 5059163, North Dakota 5690763 58103
Site Public Contact
605-312-3320
Fargo 5059163, North Dakota 5690763 58104
Site Public Contact
800-437-4010
Fargo 5059163, North Dakota 5690763 58122
Fargo 5059163, North Dakota 5690763 58122
Jamestown 5059836, North Dakota 5690763 58401
Avon 5146277, Ohio 5165418 44011
Site Public Contact
800-641-2422
Beachwood 5146711, Ohio 5165418 44122
Belpre 4506187, Ohio 5165418 45714
Centerville 4508204, Ohio 5165418 45459
Chillicothe 4828890, Ohio 5165418 45601
Cincinnati 4508722, Ohio 5165418 45219
Cincinnati 4508722, Ohio 5165418 45220
Cincinnati 4508722, Ohio 5165418 45242
Cincinnati 4508722, Ohio 5165418 45247
Cincinnati 4508722, Ohio 5165418 45255
Cleveland 5150529, Ohio 5165418 44106
Columbus 4509177, Ohio 5165418 43210
Columbus 4509177, Ohio 5165418 43213
Columbus 4509177, Ohio 5165418 43219
Columbus 4509177, Ohio 5165418 43222
Dayton 4509884, Ohio 5165418 45409
Dayton 4509884, Ohio 5165418 45409
Site Public Contact
937-276-8320
Dayton 4509884, Ohio 5165418 45415
Franklin 4512203, Ohio 5165418 45005-1066
Gahanna 5155393, Ohio 5165418 43230
Greenville 5156493, Ohio 5165418 45331
Site Public Contact
937-569-7515
Grove City 4513409, Ohio 5165418 43123
Grove City 4513409, Ohio 5165418 43123
Lancaster 4516233, Ohio 5165418 43130
Lima 5160783, Ohio 5165418 45801
Marietta 4517586, Ohio 5165418 45750
Marysville 5162077, Ohio 5165418 43040
Maumee 5162137, Ohio 5165418 43537
Mount Vernon 5163799, Ohio 5165418 43050
New Albany 5164202, Ohio 5165418 43054
Newark 5164466, Ohio 5165418 43055
Newark 5164466, Ohio 5165418 43055
Perrysburg 5166516, Ohio 5165418 43551
Portsmouth 4521816, Ohio 5165418 45662
Sandusky 5170691, Ohio 5165418 44870
Springfield 4525353, Ohio 5165418 45504
Springfield 4525353, Ohio 5165418 45504
Toledo 5174035, Ohio 5165418 43608
Toledo 5174035, Ohio 5165418 43623
Toledo 5174035, Ohio 5165418 43623
Toledo 5174035, Ohio 5165418 43623
Site Public Contact
800-444-3561
Troy 5174358, Ohio 5165418 45373
West Chester 4520522, Ohio 5165418 45069
Westerville 5176472, Ohio 5165418 43081
Wilmington 4528463, Ohio 5165418 45177
Zanesville 4528923, Ohio 5165418 43701
Oklahoma City 4544349, Oklahoma 4544379 73120
Site Public Contact
405-752-3402
Baker City 5712169, Oregon 5744337 97814
Ontario 5744166, Oregon 5744337 97914
Allentown 5178127, Pennsylvania 6254927 18103
Bethlehem 5180225, Pennsylvania 6254927 18017
Danville 5186327, Pennsylvania 6254927 17822
East Stroudsburg 5188075, Pennsylvania 6254927 18301
Hazleton 5193011, Pennsylvania 6254927 18201
Hazleton 5193011, Pennsylvania 6254927 18201
Lewisburg 5197842, Pennsylvania 6254927 17837
Pottsville 5207080, Pennsylvania 6254927 17901
Scranton 5211303, Pennsylvania 6254927 18510
Wilkes-Barre 5219488, Pennsylvania 6254927 18711
Willow Grove 5219619, Pennsylvania 6254927 19090
Gaffney 4579418, South Carolina 4597040 29341
Greer 4580599, South Carolina 4597040 29651
Spartanburg 4597200, South Carolina 4597040 29303
Site Public Contact
864-560-6812
Spartanburg 4597200, South Carolina 4597040 29303
Spartanburg 4597200, South Carolina 4597040 29307
Site Public Contact
864-560-6812
Union 4599214, South Carolina 4597040 29379
Sioux Falls 5231851, South Dakota 5769223 57104
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Berlin Corners 5233780, Vermont 5242283 05602
Site Public Contact
802-225-5400
Burlington 5234372, Vermont 5242283 05401
Burlington 5234372, Vermont 5242283 05405
Bremerton 5788054, Washington 5815135 98310
Port Townsend 5807239, Washington 5815135 98368
Site Public Contact
360-344-3091
Silverdale 5810490, Washington 5815135 98383
Ashland 5244247, Wisconsin 5279468 54806
Ashland 5244247, Wisconsin 5279468 54806
Chippewa Falls 5248511, Wisconsin 5279468 54729
Eau Claire 5251436, Wisconsin 5279468 54701
Hayward 5255882, Wisconsin 5279468 54843
Ladysmith 5259048, Wisconsin 5279468 54848
Marshfield 5261969, Wisconsin 5279468 54449
Milwaukee 5263045, Wisconsin 5279468 53226
Site Public Contact
414-805-3666
Minocqua 5263156, Wisconsin 5279468 54548
Mukwonago 5263965, Wisconsin 5279468 53149
Oconomowoc 5265499, Wisconsin 5279468 53066
Site Public Contact
262-928-7878
Rice Lake 5268798, Wisconsin 5279468 54868
Spooner 5274034, Wisconsin 5279468 54801
Stevens Point 5274644, Wisconsin 5279468 54482
Superior 5275191, Wisconsin 5279468 54880
Site Public Contact
701-364-6272
Waukesha 5278052, Wisconsin 5279468 53188
Site Public Contact
262-928-7632
Waukesha 5278052, Wisconsin 5279468 53188
Wausau 5278120, Wisconsin 5279468 54401
Weston 5278693, Wisconsin 5279468 54476
Wisconsin Rapids 5279436, Wisconsin 5279468 54494
Cody 5821593, Wyoming 5843591 82414
Sheridan 5838198, Wyoming 5843591 82801
More Details
- NCT ID
- NCT04462406
- Status
- Recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
Detailed Description
PRIMARY OBJECTIVE: I. To determine the 12 month event free survival (EFS) rate following discontinuation of anti-PD-1 therapy in patients with disease control and negative fludeoxyglucose F-18 (FDG)- positron emission tomography (PET)/computed tomography (CT) scan or biopsy for residual disease after 12 months of anti-PD-1 therapy (Arm A). SECONDARY OBJECTIVES: I. To determine rates of pathologic response in patients with tumor biopsies where positive hypermetabolic activity was present on FDG-PET/CT scan after 12 months of anti-PD-1 therapy (Arm B). II. To determine the overall 24 month EFS. III. To determine overall survival from start of anti-PD-1 therapy. IV. To determine percentage for patients who remain on treatment beyond 12 months because of positive FDG-PET/CT scan and positive biopsy for residual disease (or unable to obtain a biopsy). V. To determine incidence rates of treatment-related adverse events beyond 12 months from start of treatment in patients who discontinue anti-PD-1 therapy at 12 months and in patients who continue anti-PD-1 therapy beyond 12 months (Arm A versus [vs.] Arm B). EXPLORATORY OBJECTIVES: I. To assess agreement in determining FDG-PET/CT positivity between the local site read and central review. II. To determine if metabolic response on serial FDG-PET/CT from pre-therapy to 12 months of anti-PD-1 therapy, as determined centrally by various criteria, is associated with EFS. III. To determine if metabolic response on serial FDG-PET/CT from 12 to 24 months after start of anti-PD-1 therapy, as determined centrally by various criteria, is associated with EFS. BIOMARKER OBJECTIVE: I. To bank tumor samples and peripheral blood for future biomarker studies. OUTLINE: Patients continue their standard of care anti-PD-1 therapy and are then assigned to 1 of 2 arms. STANDARD OF CARE: Treatment may consist of the following regimens: 1) nivolumab intravenously (IV) over 30 minutes every 2 weeks (Q2W) or every 4 weeks (Q4W); 2) pembrolizumab IV over 30 minutes every 3 weeks (Q3W) or every 6 weeks (Q6W); 3) nivolumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by nivolumab IV over 30 minutes Q2W or Q4W; or 4) pembrolizumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by pembrolizumab IV over 30 minutes Q3W or Q6W. Treatment continues until 52 weeks from start of standard of care anti-PD-1 therapy in the absence of disease progression or unacceptable toxicity. ARM A: Patients with a negative FDG-PET/CT scan or a positive FDG-PET/CT scan but with a negative biopsy for viable tumor discontinue the anti-PD-1 therapy and undergo active surveillance. ARM B: Patients with a positive FDG-PET/CT scan and positive biopsy for viable tumor or a positive FDG-PET/CT scan and biopsy not performed continue their standard of care anti-PD-1 therapy for 12 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up through week 97 and then every 3 months for up to 5 years.